Junxiao Hu, PhD
Assistant Professor, Pediatrics-Endocrinology

Publications

• Gao D, Hu J, Bradley CJ, Yang F. Instrumental variable analysis for cost outcome: Application to the effect of primary care visit on medical cost among low-income adults. Stat Med. 2023 Oct 30;42(24):4349-4376. PubMed PMID: 37828812
• Hu J, Alami V, Zhuang Y, Alzofon N, Jimeno A, Gao D. Integrated variant allele frequency analysis pipeline and R package: easyVAF. Mol Carcinog. 2023 Dec;62(12):1877-1887. PubMed PMID: 37606183
• Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 Jun;3(6):1004-1012. PubMed PMID: 37377613
• Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, Carneiro BA, Mega A, Singla N, Meguid C, George S, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay RR, Lam ET. Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study. EClinicalMedicine. 2023 Jun;60:102018. PubMed PMID: 37304495
• Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clin Genitourin Cancer. 2023 Aug;21(4):483-490. PubMed PMID: 37193610
• Gilbert D, Hu J, Medina T, Kessler ER, Lam ET. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors. Hum Vaccin Immunother. 2023 Dec 31;19(1):2207438. PubMed PMID: 37157982
• Piper M, Ross RB, Hu J, Watanabe S, Knitz M, Mehrotra S, Shulick R, Chiaro MD, Karam SD. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):627-639. PubMed PMID: 36599398
• Roy, Savannah C., Junxiao Hu, and S. Lindsey Davis. "1258 Clinical and demographic factors associated with immune related adverse events among those treated with immune checkpoint inhibitors." (2023).
• Zhu, Jessica, Junxiao Hu, and Elaine T. Lam. "Abstract C136: VHL, PBRM1, and BAP1 mutation variants and response to first-line therapies in patients with metastatic clear-cell renal cell carcinoma (mRCC)." Molecular Cancer Therapeutics 22.12_Supplement (2023): C136-C136.
• Eule, Corbin Jeffrey, Junxiao Hu, Danielle Gilbert, Joy Eskandar, and Elaine T. Lam. "Bone health practices in metastatic prostate cancer (mPCA)." (2023): e17119-e17119.
• Evans, Edward J., Neetha Paul-Eduthan, Junxiao Hu, Dexiang Gao, Matthew Galbraith, Joaquin Espinosa, and James DeGregori. "Clonal hematopoiesis in Down syndrome and its potential impact on hematopoietic lineages." Cancer Research 83, no. 7_Supplement (2023): 1510-1510.
• Lentz, Robert William, Junxiao Hu, Patrick Jud Blatchford, Todd Pitts, Alexis Diane Leal, Sunnie S. Kim, S. Lindsey Davis et al. "Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01)." (2023): TPS257-TPS257.
• Gilbert, Danielle, Junxiao Hu, and Elaine T. Lam. "COVID-19 vaccines in patients with solid tumor cancers receiving immune checkpoint inhibitors." Cancer Research 83, no. 7_Supplement (2023): 797-797.
• Leary, Jacob Beck, Junxiao Hu, Sean Davis, Alexis Diane Leal, S. Lindsey Davis, Sunnie S. Kim, Robert William Lentz et al. "Impact of early-onset colorectal cancer on utilization of chemotherapy and outcomes in patients with stage II disease." (2023): 85-85.
• Bang, T. J., Hu, J., Patil, T., Barón, A. E., Gao, D., Yang, J. C. H., ... & Camidge, D. R. (2022). The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX). Clinical Lung Cancer.
• Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 Sep 15;28(18):4092-4104. PubMed PMID: 35180772
• Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2022 Nov;3(11):1300-1317. PubMed PMID: 36434392
• Bang TJ, Hu J, Patil T, Barón AE, Gao D, Yang JC, Kuo HY, Huang HC, Sachs PB, Camidge DR. The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX). Clin Lung Cancer. 2022 Dec;23(8):e501-e509. PubMed PMID: 36100512
• Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 Sep 15;28(18):4092-4104. PubMed PMID: 35180772
• Gilbert, D., Hu, J., Kessler, E. R., & Lam, E. T. (2022). COVID-19 vaccine and incidence of severe immune-mediated adverse events in patients with renal cell carcinoma (RCC) on checkpoint inhibitor immunotherapy (CPI).
• Sheneman, D., Hu, J., Das, S., & Lieu, C. H. (2022). Chemotherapy delivery in early-onset colorectal cancer is impacted by urban versus rural settings in Colorado.
• Kolb JM, Hu J, DeSanto K, Gao D, Singh S, Imperiale T, Lieberman DA, Boland CR, Patel SG. Early-Age Onset Colorectal Neoplasia in Average-Risk Individuals Undergoing Screening Colonoscopy: A Systematic Review and Meta-Analysis. Gastroenterology. 2021 Oct;161(4):1145-1155.e12. PubMed PMID: 34119517
• Goldstein NB, Steel A, Barbulescu CC, Koster MI, Wright MJ, Jones KL, Gao B, Ward B, Woessner B, Trottier Z, Pakieser J, Hu J, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. J Invest Dermatol. 2021 Mar;141(3):638-647.e13. PubMed PMID: 32800877
• Duarte C, Beuselinck B, Weise N, Dizman N, Collier K, Li H, Martinez Chanza N, Elias R, Rose TL, Brugarolas J, Agarwal N. Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.
• Lentz RW, Friedrich T, Hu J, Leal AD, Kim SS, Davis SL, Purcell T, Messersmith WA, Lieu CH. Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
• Friedrich T, Hu J, Lentz RW, Leal AD, Kim SS, Messersmith WA, Davis SL, McCarter M, Ahrendt SA, Gleisner A, Lieu CH. Utility of chemotherapy given before and/or after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases.
• Kolb JM, Hu J, DeSanto K, Gao D, Singh S, Imperiale T, Lieberman DA, Boland CR, Patel SG. Early-Age Onset Colorectal Neoplasia in Average-Risk Individuals Undergoing Screening Colonoscopy: A Systematic Review and Meta-Analysis. Gastroenterology. 2021 Oct;161(4):1145-1155.e12. PubMed PMID: 34119517
• Goldstein NB, Steel A, Barbulescu CC, Koster MI, Wright MJ, Jones KL, Gao B, Ward B, Woessner B, Trottier Z, Pakieser J, Hu J, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. J Invest Dermatol. 2021 Mar;141(3):638-647.e13. PubMed PMID: 32800877
• Kessler, E. R., Hu, J., Srivastava, G., Kemme, D. J., Iruku, P., Rana, V., ... & Lam, E. T. (2021). Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
• Lentz, R. W., Friedrich, T., Hu, J., Leal, A. D., Kim, S. S., Davis, S. L., ... & Lieu, C. H. (2021). Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
• Duarte, C., Beuselinck, B., Weise, N., Dizman, N., Collier, K., Li, H., ... & Lam, E. T. (2021). Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.
• Patil, T., Nie, Y., Hu, J., Schenk, E. L., Pacheco, J. M., Purcell, W. T., ... & Camidge, D. R. (2021). Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.
• Friedrich, T., Hu, J., Lentz, R. W., Leal, A. D., Kim, S. S., Messersmith, W. A., ... & Lieu, C. H. (2021). Utility of chemotherapy given before and/or after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases.
• Eule, C., Hu, J., Al-Saadi, S., Collier, K., Boland, P. J., McKay, R. R., ... & Lam, E. T. (2022). Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC).
• Borges VF, Hu J, Young C, Maggard J, Parris HJ, Gao D, Lyons TR. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer. 2020;6:56. PubMed PMID: 33088913
• Jordan K, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval. Clin Cancer Res. 2020 Sep 14. [Epub ahead of print] PubMed PMID: 32928797
• Hu J, Blatchford PJ, Goldenberg NA, Kittelson JM. Group sequential designs for clinical trials with bivariate endpoints. Stat Med. 2020 Nov 20;39(26):3823-3839. PubMed PMID: 33048360
• Goldstein NB, Steel A, Barbulescu CC, Koster MI, Wright MJ, Jones KL, Gao B, Ward B, Woessner B, Trottier Z, Pakieser J, Hu J, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. MELANOCYTE PRECURSORS IN THE HAIR FOLLICLE BULGE OF REPIGMENTED VITILIGO SKIN ARE CONTROLLED BY RHO-GTPase, KCTD10 AND CTNNB1 SIGNALING. J Invest Dermatol. 2020 Aug 12. [Epub ahead of print] PubMed PMID: 32800877
• Patel SG, Ahnen DJ, Gumidyala A, Espinoza J, Nicklawsky A, Hu J, Smith D, Lowery J, Austin G, Cockburn M. Poor Knowledge of Personal and Familial Colorectal Cancer Risk and Screening Recommendations Associated with Advanced Colorectal Polyps. Dig Dis Sci. 2020 Sep;65(9):2542-2550. PubMed PMID: 32144601
• Borges VF, Hu J, Young C, Maggard J, Parris HJ, Gao D, Lyons TR. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer. 2020;6:56. PubMed PMID: 33088913
• Hu J, Blatchford PJ, Goldenberg NA, Kittelson JM. Group sequential designs for clinical trials with bivariate endpoints. Stat Med. 2020 Nov 20;39(26):3823-3839. PubMed PMID: 33048360
• Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 1;26(23):6362-6373. PubMed PMID: 32928797
• Patel SG, Ahnen DJ, Gumidyala A, Espinoza J, Nicklawsky A, Hu J, Smith D, Lowery J, Austin G, Cockburn M. Poor Knowledge of Personal and Familial Colorectal Cancer Risk and Screening Recommendations Associated with Advanced Colorectal Polyps. Dig Dis Sci. 2020 Sep;65(9):2542-2550. PubMed PMID: 32144601
• Duarte C, Martinez Chanza N, Collier K, Dizman N, Rathi N, McKay RR, Panian J, Narayan V, Carneiro BA, Mega AE, Hu J. Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC).
• Patil T, Nie Y, Hu J, Schenk EL, Pacheco JM, Purcell WT, Bunn PA, Camidge DR. Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.
• Kessler ER, Hu J, Srivastava G, Kemme DJ, Iruku P, Rana V, Schuster SR, Amirault M, Callihan E, Flaig TW, Lam ET. Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
• Borges, V. F., Hu, J., Young, C., Maggard, J., Parris, H. J., Gao, D., & Lyons, T. R. (2020). Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ breast cancer, 6(1), 1-6.
• Hu, J., Blatchford, P. J., Goldenberg, N. A., & Kittelson, J. M. (2020). Group sequential designs for clinical trials with bivariate endpoints. Statistics in Medicine, 39(26), 3823-3839.
• Patel, S. G., Ahnen, D. J., Gumidyala, A., Espinoza, J., Nicklawsky, A., Hu, J., ... & Cockburn, M. (2020). Poor knowledge of personal and familial colorectal cancer risk and screening recommendations associated with advanced colorectal polyps. Digestive diseases and sciences, 65(9), 2542-2550.
• Jordan, K. R., Sikora, M. J., Slansky, J. E., Minic, A., Richer, J. K., Moroney, M. R., ... & Bitler, B. G. (2020). The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free IntervalTherapy-induced Remodeling of the Tumor Microenvironment. Clinical Cancer Research, 26(23), 6362-6373.
• Duarte C, Martinez Chanza N, Collier K, Dizman N, Rathi N, McKay RR, Panian J, Narayan V, Carneiro BA, Mega AE, Hu J. Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC).
• Hu, J. (2019). Design and Application of Sequential Clinical Trials With Bivariate Outcomes. University of Colorado Denver, Anschutz Medical Campus.
• Reinhold, D., Morrow, J. D., Jacobson, S., Hu, J., Ringel, B., Seibold, M. A., ... & Bowler, R. P. (2017). Meta-analysis of peripheral blood gene expression modules for COPD phenotypes. PloS one, 12(10), e0185682.